Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLG) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 193,300 shares, a growth of 48.2% from the February 13th total of 130,400 shares. Based on an average daily volume of 218,900 shares, the short-interest ratio is presently 0.9 days. Approximately 36.2% of the shares of the company are sold short.

Bone Biologics Trading Up 0.3 %

NASDAQ BBLG opened at $0.83 on Friday. Bone Biologics has a one year low of $0.71 and a one year high of $4.25. The business’s fifty day moving average is $0.99 and its 200-day moving average is $1.27.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.